Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A

Circulation

Volumn 96, Issue 9, 1997, Pages 3116-3123

  Smith, Carolyn J ^a   Huang, Raymond ^a   Sun, Dong ^a   Ricketts, Sidonnie ^a   Hoegler, Carl ^a,c   Ding, Jia Zhen ^b   Moggio, Richard A ^b   Hintze, Thomas H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c Marymount College   (United States)

Author keywords

Heart failure; Inotropic agents; Pacing

Indexed keywords

CYCLIC AMP PHOSPHODIESTERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MILRINONE; RNA 18S;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HEART DILATATION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART PACING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0030723978     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.9.3116     Document Type: Article

References (45)

1. Schmitz W, Boknik P, Linck B, Muller FU. Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Mol Cell Biochem. 1996;157:251-258.
2. Homcy CJ, Vatner SF, Vatner DE. Beta-adrenergic receptor regulation in the heart in pathophysiologic states: abnormal adrenergic responsiveness in cardiac disease. Annu Rev Physiol. 1991;53: 137-159.
3. Remme WJ. Inodilator therapy for heart failure: early, late, or not at all? Circulation. 1993;87(suppl IV):IV-97-IV-107.
4. +2 sensitization. Mol Cell Biochem. 1996; 157:245-249.
5. Feldman MD, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, Grossman W, Morgan JP. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with endstage heart failure. Circulation. 1987;75:331-339.
6. von der Leyen H, Mende U, Meyer W, Neumann J, Nose M, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, Döring V, Kalmár P, Haverich A. Mechanism underlying the reduced positive inotropic effects of phosphodiesterase inhibitors pimobendan, adibendan and saterinone in failing as compared Io non-failing human cardiac muscle preparations. Naunyn-Schmiedeberg's Arch Pharmacol. 1991;344:90-100.
7. Perreault CL, Shannon RP, Komamura K, Vatner SF, Morgan JP. Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J Clin Invest. 1990;89:932-938.
8. m cyclic nucleotide phosphodiesterase isozymes in human cardiac muscle from normal and cardiomyopathic subjects. Second Messengers Phosphoproteins. 1990;13:13-25.
9. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC. Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest. 1991;88:15-19.
10. Meacci E, Taira M, Moos M, Jr., Smith CJ, Movsesian MA, Degerman E, Belfrage P, Manganiello VC. Molecular cloning and expression of human myocardial cGMP- inhibited cAMP phosphodiesterase. Proc Natl Acad Sci USA. 1992;89:3721-3725.
11. Taira M, Hockman SC, Calvo JC, Belfrage P, Manganiello VC. Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J Biol Chem. 1993;268:18573-18579.
12. Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, Manganiello VC, Bondy CA. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J Clin Invest. 1995;95:1528-1538.
13. m, cGMP-inhibiled cAMP phosphodiesterase in cardiac and skeletal muscle. Biochem Biophys Res Commun. 1996;225:1058-1062.
14. Kasuya J, Goko H, Fujita-Yamaguchi Y. Multiple transcripts for the human cardiac form of the cGMP-inhibited cAMP phosphodiesterase. J Biol Chem. 1995;270:14305-14312.
15. Degerman E, Belfrage P, Manganiello VC. cGMP-inhibited phosphodiesterases (PDE3 gene family). Biochem Soc Transm. 1996;24: 1010-1013.
16. m, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem Biophys Res Commun. 1993;190:516-521.
17. Smith CJ, Vasta V, Degerman E, Belfrage P, Manganiello VC. Hormone-sensitive cyclic GMP-inhibited cyclic AMP phosphodiesterase in rat adipocytes: regulation of insulin- and cAMP-dependent activation by phosphorylation. J Biol Chem. 1991;266: 13385-13390.
18. Macphee CH, Reifsnyder DH, Moore TA, Lerea KM, Beavo JA. Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets. J Biol Chem. 1988;263:10353-10358.
19. Leroy M-J, Degerman E, Taira M, Murata T, Wang LH, Movsesian MA, Meacci E, Manganiello VC. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry. 1996;35:10194-10202.
20. Kauffman RF, Crowe VG, Utterback BG, Robertson DW. LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol Pharmacol. 1986;30:609-616.
21. Pillai R, Fluckiger Staub S, Colicelli J. Mutational mapping of kinetic and pharmacological properties of a human cardiac cAMP phosphodiesterase. J Biol Chem. 1994;269:30676-36681.
22. Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility Circ Res. 1987;61:539-547.
23. Smith CJ, Sun D, Hoegler C, Roth BS, Zhang X, Zhao G, Xu X, Kobari Y, Pritchard Jr. K, Sessa WC, Hintze TH. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res. 1996;78:58-64.
24. Zhao G, Shen W, Xu X, Ochoa M, Bernstein R, Hintze TH. Selective impairment of vagally mediated, nitric oxide-dependent coronary vasodilation in conscious dogs after pacing-induced heart failure. Circulation. 1995;91:2655-2663.
25. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18:5294-5299.
26. Swinnen JV, Tsikalas KE, Conti M. Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. J Biol Chem. 1991;266:18370-18377.
27. Conti M, Nemoz G, Sette C, Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev. 1995;16:370-389.
28. Bolger GB, Rodgers L, Riggs M. Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene. 1994;149:237-244.
29. Lugnier C, Muller B, LeBec A, Beaudry C, Rousseau E. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther. 1993;265:1142-1151.
30. Colicelli J, Birchmeier C, Michaeli T, O'Neill K, Riggs M, Wigler M. Isolation and characterization of a mammalian gene encoding a high-affinity cAMP phosphodiesterase. Proc Natl Acad Sci U S A. 1989;86:3599-3603.
31. Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA, Wigler M. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficicnt Saccharomyces cerevisiae. J Biol Chem. 1993;268:12925-12932.
32. Kajstura J, Zhang X, Liu Y, Szoke E, Cheng W, Olivetti G, Hintze TH, Anversa P. Cellular basis of pacing-induced dilated cardiomyopathy: myocyte cell loss and myocyte cellular hypertrophy. Circulation. 1995;92:2306-2317.
33. Liu Y, Cignola E, Cheng W, Kajstura J, Olivetti G, Hintze TH, Anversa P. Myocyte nuclear mitotic division and programmed cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest. 1995;73:771-787.
34. Perreault CL, Shannon RP, Shen Y, Vatner SF, Morgan JP. Excitation-contraction coupling in isolated myocardium from dogs with compensated left ventricular hypertrophy. Am J Physiol 1994; 266:H2436-H2442.
35. Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, Bristow MR. Pharmacologic and hemodynamic effects of combined β-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995;108:1524-1532.
36. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL. Effects of oral milrinone on mortality in severe chronic heart failure N Engl J Med. 1989;325:1468-1475.
37. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone: suppression of natural killer cell activity and tumor necrosis-α production. J Clin Invest. 1994;94: 1212-1217.
38. Sato Y, Matsumori A, Sasayama S. Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells. J Mol Cell Cardiol. 1995;27: 2265-2273.
39. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepaine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 1993;329:149-155.
40. Nony P, Boissel J-P, Lievre M, Leizorovicz A, Haugh MC, Fareh S, de Breyne B. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients: a meta-analysis. Eur J Clin Pharmacol. 1994;46:191-196.
41. Lopez Aparicio P, Belfrage P, Manganiello VC, Kono T, Degerman E. Stimulation by insulin of a serine kinase in human platelets that phosphorylates and activates the cGMP-inhibited cAMP phosphodiesterase. Biochem Biophys Res Commun. 1993;193:1137-1144.
42. Borchert G, Bartel S, Beyerdorfer I, Kuttner I, Szekeres L, Krause E-G. Long-lasting anti-adrenergic effect of 7-oxo-prostacyclin in the heart: a cycloheximide sensitive increase of phosphodiesterase isoform I and IV activities. Mol Cell Biochem. 1994;132:57-67.
43. m, cyclic nucleotide phosphodiesterase activities in rat adipocytes. J Biol Chem. 1985;260:82-85.
44. Elks ME, Manganiello VC. Effects of thyroid hormone on regulation of lipolysis and adenosine 3′,5′-monophosphate metabolism in 3T3-L1 adipocytes. Endocrinology. 1985;117:947-953.
45. Correze C, Thibout H. Effects of thyroidectomy, insulin and phospholipids on cyclic AMP phosphodiesterase in rat adipocyte plasma membranes. J Cyc Nucl Prot Phos Res. 1985;10:167-178.